Retinitis Pigmentosa Market By Treatment Type (Pharmacological Treatments, Gene Therapy, Retinal Prosthetics & Devices, Cell & Surgical Therapy); By Inheritance Pattern (Autosomal Recessive Retinitis Pigmentosa, Autosomal Dominant Retinitis Pigmentosa, X-Linked Retinitis Pigmentosa); By Diagnostic Method (Electroretinography [ERG], Visual Field Testing, Genetic Testing); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Retinitis Pigmentosa Market: Gene Therapy and Genetic Diagnosis Expand Treatment Value – (Updated On: 1st-Oct-2026)

The Global Retinitis Pigmentosa Market was estimated at USD 546.40 million in 2025 and is projected to reach USD 906.50 million by 2032, registering a CAGR of 7.50% during 2026–2032.

 

Retinitis pigmentosa (RP) is a group of inherited retinal disorders in which rod photoreceptors generally degenerate first, causing night blindness and progressive peripheral or tunnel-vision loss, followed by cone involvement that can impair central and color vision.

 

The addressable clinical burden remains substantial, with more than 1.5 million people affected by Retinitis Pigmentosa globally and an estimated prevalence of approximately 1 in 4,000 individuals. In the United States, around 100,000 people are living with Retinitis Pigmentosa, creating a sizeable patient base for genetic testing, retinal monitoring, therapeutic intervention, and vision-support services. Data from the U.S. IRIS Registry covering 38,179 patients with Retinitis Pigmentosa showed that 42.9% developed cataracts, 12.8% underwent cataract surgery, and 16.1% were diagnosed with cystoid macular edema, indicating a significant secondary treatment burden alongside the underlying inherited retinal disease.

 

Pipeline activity is increasingly focused on gene and cell-based therapies that target the underlying causes of Retinitis Pigmentosa. LUXTURNA established the commercial precedent for ocular gene therapy in patients with confirmed biallelic RPE65 mutations, while Beacon Therapeutics is advancing laru-zova, Ocugen is developing OCU400, and Nanoscope Therapeutics is progressing MCO-010. MeiraGTx and Johnson & Johnson are also developing botaretigene sparoparvovec, while Ray Therapeutics is advancing RTx-015, broadening the future treatment pipeline across multiple RP genotypes and disease stages.

 

Overall market growth is increasingly being shaped by the transition from lifelong supportive care toward genetically guided diagnosis, one-time gene therapies, mutation-agnostic approaches, and vision-restoration technologies, which can substantially increase treatment value per eligible patient.

 

Segment Leadership and Emerging Growth Hotspots in the Retinitis Pigmentosa Market

Leading Subsegments

Pharmacological Treatments Lead by Treatment Type

Pharmacological Treatments account for an estimated 39% share of the Retinitis Pigmentosa Market, equivalent to approximately USD 213.10 million in 2025 revenue, and are projected to expand at a CAGR of 5.20% during 2026–2032. Market demand is supported by vitamin A supplementation for selected patients and carbonic anhydrase inhibitors such as acetazolamide and dorzolamide for RP-associated cystoid macular edema. Emerging neuroprotective, anti-inflammatory, antioxidant, and mutation-targeted therapies are expanding the clinical pipeline and could broaden future treatment opportunities beyond complication management.

Autosomal Recessive RP Forms the Largest Modeled Inheritance Segment

Autosomal Recessive Retinitis Pigmentosa accounts for an estimated 54% market share, representing approximately USD 295.06 million in 2025 revenue, and is projected to expand at a CAGR of 6.60% during 2026–2032. arRP represents roughly 50%–60% of genetically resolved Retinitis Pigmentosa cases, creating a substantial patient pool for genetic testing, retinal imaging, supportive therapies, and emerging gene-based treatments. Mutations in genes such as USH2A, PDE6A, and PDE6B, combined with earlier disease onset and progressive vision loss, sustain long-term treatment demand.

Electroretinography Retains the Largest Diagnostic Revenue Base

Electroretinography (ERG) accounts for an estimated 42% share of the diagnostic-method segment, equivalent to approximately USD 229.49 million in 2025 revenue, and is projected to grow at a CAGR of 5.70% during 2026–2032. In the Retinitis Pigmentosa Market, ERG supports early and subclinical diagnosis by detecting retinal functional loss before visible structural changes. It differentiates rod and cone dysfunction, evaluates a-wave and b-wave abnormalities, tracks disease progression, and provides functional endpoints for gene-therapy and retinal-implant clinical trials.

North America Maintains the Largest Regional Revenue Pool

North America represents an estimated 41% of the global Retinitis Pigmentosa Market, generating approximately USD 224.02 million in revenue in 2025. The region is projected to expand at a CAGR of 6.60% during 2026–2032. Market demand is supported by the high clinical burden of retinitis pigmentosa, widely recognized as the most common group of inherited retinal dystrophies in North America, affecting patients across demographic groups and sustaining demand for diagnosis, genetic testing, disease monitoring, specialized care, and emerging treatment options.

 

Fastest-Growing Subsegments

Gene Therapy Moves Toward the Fastest Treatment-Type Expansion

Gene Therapy represents an estimated 31% share of the Retinitis Pigmentosa Market, generating approximately USD 169.38 million in 2025 revenue, and is projected to record the fastest treatment-type CAGR of 10.80% during 2026–2032. Gene therapy approaches aim to slow, stop, or potentially reverse vision loss by replacing defective genes, correcting disease-causing mutations, or improving retinal cell survival. Current development includes RPE65-targeted therapy, RPGR and USH2A programs, mutation-agnostic platforms such as OCU400, optogenetics, and CRISPR-based gene editing for inherited retinal degeneration.

X-Linked RP Emerges as the Fastest-Growing Inheritance Segment

X-Linked Retinitis Pigmentosa accounts for an estimated 18% market share, representing approximately USD 98.35 million in 2025 revenue, and is projected to record the fastest inheritance-segment CAGR of 11.40% during 2026–2032. XLRP represents roughly 10%–15% of all retinitis pigmentosa cases and is among its most severe, rapidly progressive hereditary forms. RPGR mutations account for approximately 70%–80% of XLRP cases, while RP2 mutations contribute about 15%, creating a genetically defined patient pool for targeted gene therapies and clinical development.

Genetic Testing Becomes the Fastest-Growing Diagnostic Segment

Genetic Testing accounts for an estimated 27% share of the retinitis pigmentosa diagnostic segment, generating approximately USD 147.53 million in 2025, and is projected to record the fastest CAGR of 11.20% during 2026–2032. Its growing market role reflects the ability to identify disease-causing mutations, confirm inheritance patterns, distinguish syndromic from nonsyndromic RP, and determine eligibility for gene-specific therapies and clinical trials. Wider testing adoption is also supporting genetic counselling, family-risk assessment, and precision treatment pathways across specialized retinal care settings.

Asia-Pacific Records the Fastest Regional Growth

Asia-Pacific accounts for an estimated 23% share of the global Retinitis Pigmentosa Market, generating approximately USD 125.67 million in 2025 revenue. The region is projected to record the fastest CAGR of 9.60% during 2026–2032, supported by expanding RP diagnostic capabilities, growing patient identification, and stronger regional research collaborations. Increasing clinical interest in inherited retinal disorders and the gradual adoption of advanced gene-based therapies are also broadening treatment opportunities and strengthening the commercial outlook for RP therapies across Asia-Pacific.

 

Competitive Landscape: Approved Gene Therapy and Late-Stage Programs Define Retinitis Pigmentosa Market Leadership

Three Leading Companies in the Retinitis Pigmentosa Market

Spark Therapeutics – Commercial Gene-Therapy Precedent

Spark Therapeutics represents the most established commercial participant in inherited retinal gene therapy through LUXTURNA (voretigene neparvovec-rzyl). The FDA-approved therapy is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, including eligible patients whose inherited retinal degeneration may present clinically as retinitis pigmentosa. LUXTURNA established an important commercial and regulatory precedent by demonstrating that a one-time, subretinally delivered gene therapy could reach the market for an inherited retinal disorder.

FDA evaluation of the pivotal Phase 3 program included 31 randomized patients aged 4–44 years, of whom 20, or 64%, were pediatric patients. The FDA concluded that treatment produced a clinically meaningful improvement in functional vision based on the multi-luminance mobility test at one year. The commercial presence of an approved ocular gene therapy also provides important infrastructure for genetic diagnosis, treatment-center qualification, retinal surgery, and reimbursement pathways that can support subsequent RP gene therapies.

Nanoscope Therapeutics – Closest Gene-Agnostic Therapy to U.S. Commercialization

Nanoscope Therapeutics has become one of the most advanced emerging companies in RP through MOGENRY, formerly MCO-010, a mutation-agnostic optogenetic gene therapy for patients with severe vision loss. On September 9, 2026, the FDA accepted and filed the company's Biologics License Application, placing MOGENRY under regulatory review. If approved, the therapy would provide a treatment approach that does not require patients to carry one specific RP-causing mutation.

The RESTORE Phase 2b study reported improvement in best-corrected visual acuity at Week 52 of 0.337 LogMAR in the high-dose group and 0.382 LogMAR in the low-dose group, versus 0.050 LogMAR in the sham-control group. The improvement exceeded 0.3 LogMAR, approximately three eye-chart lines, in both treatment groups. Long-term REMAIN follow-up subsequently showed vision gains sustained for approximately three years, while the company reported four-year follow-up data in September 2026. Nanoscope's gene-agnostic strategy is particularly relevant commercially because RP involves mutations across a very large number of different genes.

Beacon Therapeutics – Pivotal X-Linked RP Program Reaches Major Clinical Milestone

Beacon Therapeutics is a leading late-stage company in X-linked retinitis pigmentosa through laruparetigene zovaparvovec, or laru-zova, targeting RPGR-associated XLRP. In September 2026, Beacon reported positive results from the pivotal VISTA trial, which met its FDA-endorsed primary endpoint and moved the program toward regulatory discussions.

The trial enrolled 85 males aged 12–48 years. At Month 12, 31.0% of patients receiving the high dose achieved an improvement of at least 15 letters in low-luminance visual acuity, compared with 24.1% in the low-dose arm and no responders in the untreated control group. The high-dose result achieved p=0.0019, while the low-dose result achieved p=0.0106. These results are commercially significant because RPGR mutations account for a substantial portion of X-linked RP, a form associated with severe and relatively early progressive vision loss.

Other Important Companies and Their Roles

• Ocugen, Inc. – OCU400: Developing a mutation-agnostic NR2E3 modifier gene therapy; its Phase 3 liMeliGhT trial completed enrollment of 140 patients, with topline results expected in Q1 2027.

• MeiraGTx – Botaretigene Sparoparvovec: Acquired full rights to bota-vec from Johnson & Johnson for USD 25 million in 2026 and is pursuing regulatory filings for RPGR-associated XLRP; the Phase 3 LUMEOS study enrolled 95 patients.

• Johnson & Johnson Innovative Medicine: Previously partnered in and sponsored development of bota-vec before transferring its interests to MeiraGTx in 2026; it remains economically linked through potential milestones and royalties.

• Ray Therapeutics – RTx-015: Developing a mutation-agnostic optogenetic therapy for advanced RP; the FDA granted RTx-015 Regenerative Medicine Advanced Therapy designation in April 2026, supporting closer interaction with regulators during development.

 

Analyst Commentary: Precision Retinal Therapies Redefine Commercial Growth

The Retinitis Pigmentosa Market is moving from long-term supportive vision management toward precision retinal therapeutics built around genetic diagnosis, gene replacement, modifier-gene strategies, and mutation-agnostic optogenetic approaches. The strongest growth opportunities are emerging in genetic testing, late-stage gene therapy programs, advanced retinal imaging, and therapies designed for patients with severe or genetically heterogeneous disease.

 

Retinitis Pigmentosa Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 546.40 Million
Revenue Forecast in 2032	USD 906.50 Million
Overall Growth Rate	CAGR of 7.50% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Inheritance Pattern, By Diagnostic Method, By Geography
By Treatment Type	Pharmacological Treatments, Gene Therapy, Retinal Prosthetics & Devices, Cell & Surgical Therapy
By Inheritance Pattern	Autosomal Recessive Retinitis Pigmentosa, Autosomal Dominant Retinitis Pigmentosa, X-Linked Retinitis Pigmentosa
By Diagnostic Method	Electroretinography (ERG), Visual Field Testing, Genetic Testing
Key Companies	Spark Therapeutics, Nanoscope Therapeutics, Beacon Therapeutics, Ocugen, Inc., MeiraGTx, Johnson & Johnson Innovative Medicine, Ray Therapeutics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	The strongest growth opportunities are emerging in genetic testing, late-stage gene therapy programs, advanced retinal imaging, and therapies designed for patients with severe or genetically heterogeneous disease.
Customization Option	Available upon request